glp-faq
All FAQs
FAQgeneral

Can I get retatrutide right now?

Retatrutide isn't FDA-approved and isn't commercially available. Here's what clinical trials, gray market sources, and the legal landscape actually look like.

Updated May 19, 2026 · 5 min read

Probably not through a legitimate channel. Retatrutide is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, currently in Phase 3 trials under the TRIUMPH program. It has not received FDA approval for any indication. That means there is no standard prescription pathway, no commercial pharmacy supply, and no legal way to purchase it as a consumer product.

The two paths that do exist — clinical trial enrollment and gray market compounded sources — are very different in terms of safety and legal standing.

Clinical trial enrollment

The cleanest legitimate way to access retatrutide before approval is to enroll in a TRIUMPH trial. Eli Lilly is running Phase 3 studies for retatrutide across obesity, type 2 diabetes, and potentially other indications.

How to find open trials:

  • Search ClinicalTrials.gov for "retatrutide" or "LY3437943" (the INN designation)
  • Filter for studies that are "recruiting" or "enrolling by invitation"
  • Check eligibility criteria — most obesity trials require BMI ≥30 (or ≥27 with a comorbidity), no active T2D for the weight management arm, and exclusions for prior GLP-1 use within a certain window

What trial participation involves:

  • You may receive retatrutide, or you may be randomized to a comparator (tirzepatide, semaglutide, or placebo depending on the study design)
  • Trial participation means regular visits, blood draws, frequent check-ins, and detailed reporting of side effects
  • You're contributing to the evidence base that will determine whether and how this drug gets approved
  • You don't pay for the drug; the trial sponsor covers drug and often some study-related costs

If the TRIUMPH program is fully enrolled, sites may no longer be recruiting — but checking is worth a few minutes.

The gray market: compounded retatrutide

Here the picture gets murkier. A number of compounding pharmacies — some domestic, many offshore — have begun offering what they call "retatrutide" or "LY3437943" peptide, typically as a research chemical or as a compounded injectable.

The legal reality: Compounding pharmacies in the U.S. operate under FDA exemptions that allow them to produce drug preparations not commercially available. However, these exemptions don't cover drugs in active investigation (i.e., drugs still in Phase 3 trials) unless the drug is on the FDA's shortage list. Retatrutide is not on any shortage list because it isn't approved. U.S.-based compounders offering retatrutide are operating outside these exemptions.

Offshore sources (often marketed as "research peptides") are neither FDA-regulated nor subject to U.S. compounding rules. Purchasing from them and importing for personal use is technically a customs violation and an FDA import policy gray area. People do it; it remains legally risky.

The safety reality: This is more serious than the legal issue. Retatrutide has completed Phase 2, not Phase 3. The Phase 3 TRIUMPH program is specifically designed to:

  • Characterize cardiovascular effects at scale (the glucagon receptor component has cardiac effects not fully characterized)
  • Identify adverse events that are rare enough to be invisible in a 300-person Phase 2 trial
  • Establish the safe dosing window in a broad population

A compounded "retatrutide" from an unlicensed pharmacy has never been tested for identity, purity, potency, or sterility by an independent body. You don't know if it's actually retatrutide, if it's dosed correctly, or if it's contaminated. For a triple-agonist drug with a novel glucagon component and an incompletely characterized cardiovascular profile, this is a meaningful risk.

The pattern with compounded tirzepatide illustrates the problem: some 503B pharmacies produced high-quality compounded tirzepatide; others produced incorrectly dosed vials that led to hospitalizations. Retatrutide compounds are operating in an even less regulated environment.

What to do if you're considering it anyway

If you've read this and are still considering gray market retatrutide, at minimum:

  • Do not use offshore "research chemical" sources — these have essentially zero quality controls
  • If you use a U.S. compounding pharmacy, verify it holds a 503B accreditation (not just 503A), has current ISO certification, and can provide a Certificate of Analysis for the specific batch
  • Start at the lowest possible dose — Phase 2 started at 1 mg weekly
  • Have your prescriber aware and monitoring your cardiovascular markers (heart rate, blood pressure)
  • Stop immediately and seek care if you develop chest pain, significant tachycardia, or severe abdominal pain

This is not a recommendation to proceed. It's a harm reduction note for people who will regardless.

The honest comparison to tirzepatide and semaglutide

The reason interest in early retatrutide access is so high is the Phase 2 data — 24.2% weight loss at 48 weeks is exceptional. But:

  • Tirzepatide at 15 mg produces ~21% weight loss at 72 weeks. For most patients, this is close to retatrutide's Phase 2 top-line number, and tirzepatide's full safety profile is established across hundreds of thousands of real-world users.
  • The incremental benefit of retatrutide over tirzepatide hasn't been measured directly. Head-to-head data doesn't exist. Some patients will respond better; others may not see a meaningful difference.
  • The approval timeline is active. The retatrutide FDA approval timeline explains what's realistic and why waiting for approved supply is the lower-risk path for most people.

If you're on tirzepatide or semaglutide and haven't reached maximum tolerated dose, that's the first optimization — not a gray market drug.

See also: